Spots Global Cancer Trial Database for sarcomatoid renal cell carcinoma

Every month we try and update this database with for sarcomatoid renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy	NCT03055013	Metastatic Rena... Sarcomatoid Ren... Stage II Renal ... Stage III Renal... Unclassified Re...	Nephrectomy Nivolumab Patient Observa...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study	NCT03793166	Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ...	Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)	NCT03177239	Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11 Translocat...	Nivolumab Ipilimumab	18 Years -	Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)	NCT03177239	Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11 Translocat...	Nivolumab Ipilimumab	18 Years -	Australian and New Zealand Urogenital and Prostate Cancer Trials Group
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma	NCT05808608	Renal Cell Carc... First-line Trea... Non Clear Cell ... Sarcomatoid Ren...	AK104 Axitinib	18 Years - 75 Years	West China Hospital
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy	NCT03055013	Metastatic Rena... Sarcomatoid Ren... Stage II Renal ... Stage III Renal... Unclassified Re...	Nephrectomy Nivolumab Patient Observa...	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer	NCT01767636	Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Pazopanib Hydro...	18 Years -	Mayo Clinic
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma	NCT06049576	Clear Cell Rena... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ...	Biospecimen Col... Bone Scan Computed Tomogr... Ipilimumab Magnetic Resona... Myrciaria dubia... Nivolumab	18 Years -	City of Hope Medical Center
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer	NCT01767636	Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Pazopanib Hydro...	18 Years -	Mayo Clinic
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	NCT03866382	Bladder Adenoca... Bladder Clear C... Bladder Mixed A... Bladder Neuroen... Bladder Small C... Bladder Squamou... Chromophobe Ren... Collecting Duct... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Kidney Medullar... Large Cell Neur... Malignant Testi... Malignant Testi... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Chro... Metastatic Kidn... Metastatic Mali... Metastatic Papi... Metastatic Peni... Metastatic Pros... Metastatic Sarc... Metastatic Uret... Papillary Renal... Sarcomatoid Ren... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Urethr... Stage IVB Prost... Urachal Adenoca... Urethral Clear ...	Bone Scan Cabozantinib S-... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)	NCT03685448	Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11.2 Transloc...	Cabozantinib	18 Years -	Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)	NCT03177239	Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11 Translocat...	Nivolumab Ipilimumab	18 Years -	Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: